» Articles » PMID: 12711484

Benign Prostatic Hyperplasia

Overview
Journal Lancet
Publisher Elsevier
Specialty General Medicine
Date 2003 Apr 25
PMID 12711484
Citations 81
Authors
Affiliations
Soon will be listed here.
Abstract

In both ageing men and women, there is an increasing incidence of lower urinary tract symptoms (LUTS) which are increasing. These infections have many possible causes, including smooth muscle dysfunction, neurological factors and benign prostatic hyperplasia. Up to 15% to 25% of men aged 50-65 years have LUTS of sufficient severity to interfere with their quality of life. Although benign prostatic hyperplasia is an important cause of these symptoms, and can have serious consequences, clinicians should be aware of these other causes so that the appropriate diagnosis is made before invasive treatments are started. New medical treatments, including alpha-adrenergic blocking agents and 5 alpha-reductase inhibitors mean that many men without complications such as infection, bleeding, or chronic retention, and with mild to moderate symptoms, should be managed in primary care. Combined local protocols between primary and secondary care will help to establish which men with persistent symptoms or complications need referral for a urological opinion to determine the need for further investigation and more invasive forms of management. We review the pathophysiology of the disease, and current approaches to investigation and management of this common problem.

Citing Articles

A comprehensive analysis of erectile dysfunction prevalence and the impact of prostate conditions on ED among US adults: evidence from NHANES 2001-2004.

Zhang Y, Zang N, Xiang Y, Lin F, Liu X, Zhang J Front Endocrinol (Lausanne). 2025; 15:1412369.

PMID: 39872316 PMC: 11769807. DOI: 10.3389/fendo.2024.1412369.


Using large administrative data for mining patients' trajectories for risk stratification: An example from urological diseases.

Koh H, Gasevic D, Rankin D, Frydenberg M, Talic S PLoS One. 2024; 19(11):e0310981.

PMID: 39536022 PMC: 11559980. DOI: 10.1371/journal.pone.0310981.


Exploring the potential mechanism of Xiaojin Pill therapy for benign prostatic hyperplasia through metabolomics and gut microbiota analysis.

Yang Y, Quan Y, Liu Y, Yang J, Chen K, You X Front Microbiol. 2024; 15:1431954.

PMID: 39234552 PMC: 11371748. DOI: 10.3389/fmicb.2024.1431954.


Predicting surgical efficacy and diagnosing histological inflammation: the clinical significance of prostate exosome proteins in benign prostatic hyperplasia.

Teng Z, Jin C, Wang S, Han Z, Zhang Y, Wang Y Transl Androl Urol. 2024; 13(6):930-939.

PMID: 38983479 PMC: 11228684. DOI: 10.21037/tau-23-655.


Giant Benign Prostatic Hyperplasia: A Case Report.

Mdivnishvili M, Khuskivadze N, Khuskivadze A Cureus. 2024; 16(5):e61295.

PMID: 38947583 PMC: 11212843. DOI: 10.7759/cureus.61295.